轩竹生物
Xuanzhu Biopharm

Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT
UNUSUAL PRICE MOVEMENTS

This announcement is made by Xuanzhu Biopharmaceutical Co., Ltd. ("**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

UNUSUAL PRICE MOVEMENTS

The board (the "**Board**") of directors (the "**Directors**") of the Company has noted the increase in the price of the H shares of the Company (the "**H Shares**") today. Having made all such enquiries with respect to the Company as are reasonable in the circumstances, the Board confirms that it is not aware of any reasons for the movements or of any information which must be announced to avoid a false market in the H Shares or of any inside information which needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POTENTIAL ACQUISITION

The Board wishes to inform that the Company is currently in preliminary discussions with certain party regarding a potential acquisition (the "**Potential Acquisition**"). As of the date of this announcement, negotiations are still ongoing. The terms and conditions regarding the Potential Acquisition are yet to be finalized and no definitive agreements have been entered into by the Group regarding the Potential Acquisition up to the date of this announcement. There is no assurance that the Potential Acquisition will materialize or eventually be consummated. As such, the Potential Acquisition may or may not proceed. The Company will comply with the relevant requirements under Chapter 14 and Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when appropriate.

Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the H Shares.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, September 17, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; (iii) Ms. Yue Xin as employee representative Director; and (iv) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.